



Role of miRNAs in Cancer—Analysis of Their Targetome

Guest Editor:

Prof. Dr. Alfons Navarro

1. Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, Department of Surgery and Surgical Specializations, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain
2. August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain
3. Thoracic Oncology Unit, Hospital Clinic, 08036 Barcelona, Spain

Deadline for manuscript submissions:
closed (31 March 2020)

Message from the Guest Editor

Dear Colleague,

MicroRNAs (miRNAs) are the best studied noncoding RNA sequences of our genome. Since the discovery of the second miRNA sequence, let-7a, in 2000, the identification of new miRNAs has increased considerably. The first evidence that miRNAs were related to cancer also came from let-7a, which was described as a tumor suppressor in 2002. Since then, it has become clear that miRNA expression is dysregulated in human cancers. In order to identify the functions of the dysregulated miRNAs, it is necessary to decipher their target genes.

More efforts are still needed to decipher the critical targets—both coding and noncoding RNAs—of the miRNAs involved in cancer and to identify their contribution to malignant transformation and metastasis. The present issue will focus on the identification of the functions of tumorigenic miRNAs through the study of their targetome in both tumor and nontumor cells, where they are transported through exosomes. The large-scale identification of miRNA targets will allow a greater understanding of the complex networks regulated by miRNAs.

- microRNAs
- targetome
- AGO-CLIP
- deep sequencing
- exosomes
- extracellular vesicles





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)